In the US, Colestipol (colestipol systemic) is a member of the drug class bile acid sequestrants and is used to treat Hyperlipoproteinemia, Hyperlipoproteinemia Type IIa - Elevated LDL and Hyperlipoproteinemia Type IIb - Elevated LDL VLDL.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Lipid lowering agent: Bile acid sequestrant
Copolymer of dietylenetriamine and 1-chloro-2,3-epoxypropane
- Colestipolum (Latin)
- Colestipol (German)
- Colestipol (French)
- Colestipol (Spanish)
- Colestipol (OS: BAN, DCF)
- U 26597 A (IS)
- Colestipol Hydrochloride (OS: USAN, BANM)
- Colestipol Hydrochloride (PH: BP 2016, USP 38)
Farmea, Israel; Pfizer, Australia; Pfizer, Belgium; Pfizer, Canada; Pfizer, Switzerland; Pfizer, Spain; Pfizer, United Kingdom; Pfizer, New Zealand; Pharmacia & Upjohn, United States
Pfizer, Denmark; Pfizer, Norway; Pfizer, Sweden
|BAN||British Approved Name|
|BANM||British Approved Name (Modified)|
|DCF||Dénomination Commune Française|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.